Yahoo Financeยท2025-10-28 11:30Core Insights - The biotech sector presents high-risk, high-reward investment opportunities, with potential breakthroughs expected from lesser-known companies [1] Company Summaries Inovio Pharma (INO) - Inovio Pharma is valued at $123.8 billion and focuses on DNA-based medicines to combat diseases such as HPV, cancer, and infectious diseases [2] - The company plans to submit its Biologics License Application (BLA) for its lead candidate INO-3107 in the second half of 2025, anticipating FDA approval and commercial launch by 2026 [3] - The consensus rating for INO stock is a "Moderate Buy," with a potential upside of 200% based on a mean target price of $7.47, and a high price estimate of $13 suggesting a possible gain of 425% in the next 12 months [4] Terns Pharmaceuticals (TERN) - Terns Pharmaceuticals is valued at $679.9 billion and is advancing small-molecule therapies for serious diseases, focusing on oncology and obesity [5] - Its lead candidate, TERN-701, is in a Phase 1 clinical trial for chronic myeloid leukemia (CML) and has shown promising early results, while the development of TERN-601 for obesity has been discontinued due to low efficacy [6] - The consensus rating for TERN stock is a "Strong Buy," with a potential upside of 101% based on a mean target price of $15.83, and a high price estimate of $28 indicating a possible gain of 257% in the next 12 months [7]